



## Fact Sheet

---

Bayer Schering Pharma Development Projects

Business Unit: Oncology

### **Development candidate DAST – Dual acting multi-kinase inhibitor for innovative cancer therapy**

- Preclinical tests indicate a broad spectrum of activity in solid tumors
  - Potential for single daily oral administration
- 

Status: June 2007

<p><b>Project description</b></p> <p>DAST (BAY 73-4506) is a novel oral substance for cancer therapy in the early stages of clinical development. The name DAST (<b>D</b>ual <b>A</b>cting <b>S</b>ignal <b>T</b>ransduction <b>I</b>nhibitor) stands for the dual mechanism of action of the active substance, which, by its inhibitory action on various enzymes (kinases), inhibits both the signalling pathways in cancer cell proliferation and also new blood vessel formation. In preclinical studies, DAST has proved to be effective in various tumor models, including pancreatic cancer, lung cancer, colon cancer, and breast cancer. Currently, two phase I clinical studies are being conducted with DAST. The first provisional data from these studies are very promising. It is expected that the first study will end in the third quarter of 2007. Phase II studies are planned to start at the end of this year.</p>	<p><b>At a glance</b></p>
	<p><b>Name of the active substance</b></p> <p>DAST: <b>D</b>ual <b>A</b>cting <b>S</b>ignal <b>T</b>ransduction <b>I</b>nhibitor (BAY 73-4506)</p>
	<p><b>Type of substance</b></p> <p>Low molecular weight substance (small molecule)</p>
	<p><b>Targeted Indication</b></p> <p>Oncology (solid tumors)</p>

<p><b>Active substance</b></p> <p>DAST (Dual Acting Signal Transduction Inhibitor) is a novel oral multi-kinase inhibitor which fights cancer via two mechanisms of action. Through two completely different signalling pathways, the substance attacks both the tumor cells directly and at the same time inhibits the formation of new blood vessels, which are essential for tumor growth. DAST inhibits various Raf kinases, which play an important role in the proliferation of cancer cells. In addition, the active substance blocks various receptors of the VEGF receptor family. The growth factor VEGF (Vascular Endothelial Growth Factor), as a signal substance, plays a central role in the formation of new blood vessels (angiogenesis). In preclinical models, DAST displayed significant anti-tumor activity. The activity was proven in a broad spectrum of solid tumors.</p>	<p><b>Administration form</b></p> <p>Tablets</p>
	<p><b>Mode of action</b></p> <p>Multi-kinase inhibitor with dual action: Inhibition of cancer cell proliferation and prevention of new blood vessel formation (anti-angiogenesis)</p>
	<p><b>Status</b></p> <ul style="list-style-type: none"> <li>▪ Two ongoing Phase I studies</li> <li>▪ End of the first study (Proof of Concept) planned for 2007</li> <li>▪ Beginning of Phase II studies planned for 2007</li> </ul>

**Bayer HealthCare**

Bayer HealthCare, a subsidiary of Bayer AG, is one of the world's leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Diabetes Care and Pharmaceuticals divisions. The pharmaceuticals business operates under the name Bayer Schering Pharma and as Bayer HealthCare Pharmaceuticals in the US and Canada. Bayer HealthCare's aim is to discover and manufacture products that will improve human and animal health worldwide.

## **Bayer Schering Pharma**

Bayer Schering Pharma is a worldwide leading specialty pharmaceutical company. Its research and business activities are focused on the following areas: Diagnostic Imaging, Hematology/Cardiology, Oncology, Primary Care, Specialized Therapeutics and Women's Healthcare. With innovative products, Bayer Schering Pharma aims for leading positions in specialized markets worldwide. Using new ideas, Bayer Schering Pharma aims to make a contribution to medical progress and strives to improve the quality of life.

## **Research and Development at Bayer Schering Pharma**

Bayer Schering Pharma concentrates its R&D activities on innovative treatment approaches for diseases with a high unmet medical need to improve patients' quality of life and prolong lives. In this context, Bayer Schering Pharma focuses on its core competencies and its many years of experience. Thus, Bayer Schering Pharma holds a leading position in many therapeutic fields: for example, in the treatment of hemophilia and multiple sclerosis, in contrast media and oral contraception. We are also striving for a leading position in oncology. With new approaches in cancer therapy, for cardiovascular diseases, gynaecological therapies and in molecular imaging, Bayer Schering Pharma aims to become an innovation leader in these fields. In addition, Bayer Schering Pharma further develops products already on the market in order to improve their application and/or extend their range of indications.

### Contacts:

**Dr. Jost Reinhard, Tel.: +49 30 468 15062**

E-mail: [jost.reinhard@bayerhealthcare.com](mailto:jost.reinhard@bayerhealthcare.com)

**Frank Richtersmeier, Tel.: +49 30 468 17661**

E-mail: [frank.richtersmeier@bayerhealthcare.com](mailto:frank.richtersmeier@bayerhealthcare.com)

### **Forward-looking statements**

This information contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in our public reports filed with the Frankfurt Stock Exchange and with the U.S. Securities and Exchange Commission (including Form 20-F). The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.